Neoadjuvant Versus Definitive Radiochemotherapy of Locoregionally Advanced Oesophageal Cancer-who Benefits?

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2022 Apr 13

PMID 35416495

Authors

Christoph Schiffner

Hans Christiansen

Iris Brandes

Gerrit Grannas

Jorn Wichmann

Roland Merten

Affiliations

Soon will be listed here.

Abstract

Purpose: For years, there have been discussions on whether neoadjuvant radiochemotherapy followed by surgery (nRCT-S) is superior to definitive radiochemotherapy (dRCT) as the standard of care for locoregionally advanced oesophageal cancer (OC). This retrospective study aimed to evaluate our patient cohort regarding differences in survival and recurrence between nRCT‑S and dRCT.

Methods: Data from 68 patients with dRCT and 33 patients with nRCT‑S treated from 2010 to 2018 were analysed. Comorbidities were recorded using the Charlson Comorbidity Index (CCI). Recurrence patterns were recorded as in-field or out-field. Kaplan-Meier analyses were used to compare survival data (overall survival [OS], progression-free survival [PFS], and locoregional control [LRC]).

Results: Patients with nRCT‑S showed significantly lower CCI values than those with dRCT (p = 0.001). The median follow-up was 47 months. The median OS times were 31 months for nRCT‑S and 12 months for dRCT (p = 0.009), the median PFS times were 11 and 9 months, respectively (p = 0.057), and the median LRC times were not reached and 23 months, respectively (p = 0.037). The only further factor with a significant impact on OS was the CCI (p = 0.016). In subgroup analyses for comorbidities regarding differences in OS, the superiority of the nRCT‑S remained almost significant for CCI values 2-6 (p = 0.061).

Conclusion: Our study showed significantly longer OS and LRC for patients with nRCT‑S than for those with dRCT. Due to different comorbidities in the groups, it can be deduced from the subgroup analysis that patients with few comorbidities seem to especially profit from nRCT‑S.

Citing Articles

Dual-tracer PET/CT protocol with [F]FDG and [Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [F]FDG in different cancer types, resulting in larger functional and gross tumor volume.

Wegen S, Weindler J, Voltin C, van Heek L, Schomacker K, Fischer T Strahlenther Onkol. 2023; 200(1):28-38.

PMID: 37584717 PMC: 10784364. DOI: 10.1007/s00066-023-02117-2.

References

Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V . Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992; 326(24):1593-8. DOI: 10.1056/NEJM199206113262403. View

Valmasoni M, Pierobon E, Zanchettin G, Briscolini D, Moletta L, Ruol A . Cervical Esophageal Cancer Treatment Strategies: A Cohort Study Appraising the Debated Role of Surgery. Ann Surg Oncol. 2018; 25(9):2747-2755. DOI: 10.1245/s10434-018-6648-6. View

Hegemann N, Koepple R, Walter F, Boeckle D, Fendler W, Angele M . Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival. Strahlenther Onkol. 2018; 194(5):435-443. DOI: 10.1007/s00066-018-1261-y. View

Schemper M, Smith T . A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17(4):343-6. DOI: 10.1016/0197-2456(96)00075-x. View

Mariette C, Dahan L, Mornex F, Maillard E, Thomas P, Meunier B . Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014; 32(23):2416-22. DOI: 10.1200/JCO.2013.53.6532. View

Noordman B, Wijnhoven B, Lagarde S, Boonstra J, Coene P, Dekker J . Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer. 2018; 18(1):142. PMC: 5801846. DOI: 10.1186/s12885-018-4034-1. View

Eyck B, van der Wilk B, Noordman B, Wijnhoven B, Lagarde S, Hartgrink H . Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer. Trials. 2021; 22(1):345. PMC: 8127221. DOI: 10.1186/s13063-021-05274-w. View

Marks L, Yorke E, Jackson A, Ten Haken R, Constine L, Eisbruch A . Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010; 76(3 Suppl):S10-9. PMC: 4041542. DOI: 10.1016/j.ijrobp.2009.07.1754. View

Borggreve A, Mook S, Verheij M, Mul V, Bergman J, Bartels-Rutten A . Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study. BMC Cancer. 2018; 18(1):1006. PMC: 6195948. DOI: 10.1186/s12885-018-4892-6. View

10.

Hermann R, Horstmann O, Haller F, Perske C, Christiansen H, Hille A . Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use?. Dis Esophagus. 2006; 19(5):329-34. DOI: 10.1111/j.1442-2050.2006.00589.x. View

11.

de Gouw D, Klarenbeek B, Driessen M, Bouwense S, van Workum F, Futterer J . Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-Analysis. J Thorac Oncol. 2019; 14(7):1156-1171. DOI: 10.1016/j.jtho.2019.04.004. View

12.

Faiz Z, van Putten M, Verhoeven R, van Sandick J, Nieuwenhuijzen G, van der Sangen M . Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer. Ann Surg Oncol. 2019; 26(4):986-995. PMC: 6399439. DOI: 10.1245/s10434-019-07181-6. View

13.

Putora P, Bedenne L, Budach W, Eisterer W, van der Gaast A, Jager R . Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland. Radiat Oncol. 2015; 10:116. PMC: 4461999. DOI: 10.1186/s13014-015-0418-4. View

14.

Nomura M, Oze I, Kodaira T, Abe T, Komori A, Narita Y . Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis. Int J Clin Oncol. 2016; 21(5):890-898. DOI: 10.1007/s10147-016-0963-3. View

15.

Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T . Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007; 25(10):1160-8. DOI: 10.1200/JCO.2005.04.7118. View

16.

Stairmand J, Signal L, Sarfati D, Jackson C, Batten L, Holdaway M . Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review. Ann Oncol. 2015; 26(7):1325-32. DOI: 10.1093/annonc/mdv025. View

17.

Dahn D, Martell J, Vorwerk H, Hess C, Becker H, Jung K . Influence of irradiated lung volumes on perioperative morbidity and mortality in patients after neoadjuvant radiochemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2009; 77(1):44-52. DOI: 10.1016/j.ijrobp.2009.04.053. View

18.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

19.

Markar S, Gronnier C, Duhamel A, Pasquer A, Thereaux J, Chalret du Rieu M . Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?. J Clin Oncol. 2015; 33(33):3866-73. DOI: 10.1200/JCO.2014.59.9092. View

20.

Stahl M, Stuschke M, Lehmann N, Meyer H, Walz M, Seeber S . Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005; 23(10):2310-7. DOI: 10.1200/JCO.2005.00.034. View